Industry News
Regenera receives ethics approval for second clinical trial
Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema. [ + ]
Cryptome CEO resigns
Cryptome Pharmaceuticals (ASX: CRP) has announced that CEO Jeffrey Travis has resigned for personal reasons. [ + ]
Rockeby says test can also apply to children
Rockeby's (ASX:RBY) laboratory-based SysCan tests for Candida antibody levels is likely to be useful for diagnosing the infection in children, a trial in Singapore has found. [ + ]
FDA approves wrinkle filler
The FDA has approved a new injectable gel, made by Genzyme and marketed by Inamed, that can be used to temporarily fill the deepest facial wrinkles. [ + ]
Prana heading for the clinic
Melbourne brain-drug developer Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) will move its is lead Alzheimer's disease drug PBT-1 (clioquinol) into a Phase II/III clinical trial in the first half of next year, with the aim of carving up to three years from the time required to deliver the drug to the clinic. [ + ]
Agenix gets green light for Phase II trial
Six weeks after filing 5600 pages of Investigational New Drug application for a Phase II trial of its ThrombioView blood-clot imaging technology, Agenix [ASX: AGX, NASDAQ OTC: AGXLY] has been given the go-ahead by the US Food and Drug Administration. [ + ]
Optiscan wins CE Mark approval, waiting on FDA
Optiscan (ASX:OIL) has received European CE Mark approval for its flexible endo-microscope, jointly developed with Pentax. But the company and its Japanese marketing partner Pentax are awaiting a go-ahead from the US Food and Drug Administration before the marketing process gets underway. [ + ]
Eqitx vaccine research results published
A research paper in the prestigious US journal Proceedings of the National Academy of Science this week has underscored the commercial potential of the platform vaccine technology being commercialised by Eqitx (ASX:EQX) subsidiary VacTX, the company has claimed. [ + ]
Burrill honours biotech's 'best of 2004'
San Francisco-based biotechnology investment bank Burrill & Co has named its 'best of biotech' for 2004. [ + ]
Bionomics names new chairman
Bionomics (ASX:BNO) has appointed former Reserve Bank economist Dr Peter Jonson as chairman, and extended the contract of chief executive officer and managing director Dr Deborah Rathjen until June 2008. [ + ]
Cotton researcher wins award
CSIRO Plant Industry researcher, Peter Reid, has received a major CSIRO award for his work on developing hardier, more productive varieties of cotton suited specifically to Australian conditions.
[ + ]New player Gateway aims to fill commercialisation gap
Perth-based biotech project management company Gateway Capital is about to step into the ring with venture capital players and investment banks, announcing today it will aim to fast-track biotech research from research institute to ASX. [ + ]
Agenix sets up deal with US firm Inverness
Agenix (ASX:AGX) subsidiary AGEN Biomedical has secured a manufacturing and technology transfer alliance with US company Inverness Medical Innovations for its animal health diagnostic products. [ + ]
Benitec lassoos new 'minicircle' plasmid technology
Queensland gene-therapy company Benitec Ltd (ASX:BLT) has licensed-in a novel, non-viral new technology from Stanford University that delivers prolonged RNAi-induced gene-silencing in mammalian cells. [ + ]
'Open-source' initiative aims to save biotech
This month, an international movement was quietly born -- one that aims to loosen the grip of the world's biggest life science corporations on key enabling technologies and patents for biotechnology R&D. [ + ]
